Form 4: Cognition Therapeutics CFO Acquires Shares

Cognition Therapeutics Inc. reports that Chief Financial Officer John Brendan Doyle acquired 8,567 shares of common stock on May 1, 2026, through a transaction covering tax withholding obligations.

Summary

• John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc., acquired 8,567 shares of common stock on May 1, 2026.
• The acquisition was a result of shares being withheld by the Issuer to cover tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, Mr. Doyle beneficially owns 618,942 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard procedural event related to executive compensation rather than a discretionary purchase or sale of stock.

Positives

• The CFO's acquisition of shares, even if through a tax withholding mechanism, indicates continued commitment to the company.
• The direct ownership of a significant number of shares (618,942) by the CFO suggests alignment with shareholder interests.

Negatives

• The transaction involved shares being withheld for tax purposes, which is a standard procedure but not a direct purchase of new shares by the executive.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this specific transaction relates to tax withholding upon vesting of RSUs, it's part of the broader landscape of executive compensation and insider equity holdings within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing provides transparency on insider holdings, reinforcing confidence in management's continued stake in the company.

Key Dates

Keywords

Form 4, SEC Filing, Cognition Therapeutics, CGTX, Insider Transaction, Stock Acquisition, Beneficial Ownership, Restricted Stock Units, Tax Withholding